Scientific Program

DAY 1 (February 22, Mon) DAY 2 (February 23, Tue)
09:00-09:40 Plenary 3: Genome Editing
09:00-09:40

PL03 Organellar DNA editing in vitro and in vivo

Jin-Soo Kim (KAIST, Korea)
09:40-10:55 Session 5. RNA & Genome Editing
09:40-10:05 S05-1 Wensheng Wei (Peking University, China)
10:05-10:30

S05-2 High-Resolution RNA Knockdown Profiles of Small RNA and Cas13 Systems

S. Chul Kwon (The University of Hong Kong, Hong Kong, China)
10:30-10:55 S05-3 Seung Ryul Han (Rznomics, Korea)
11:15-12:15 Session 6. Short Talks (Selected from Abstracts)
11:15-11:25

S06-1 Enhancing Translational Validity: Integrating Welfare, Behavioral Enrichment, and the 3Rs into Non-Human Primate Models for Oligonucleotide Therapeutics Development

Hanna Suh (Korea Institute of Toxicology, Korea)
11:25-11:35 S06-2 TBD
11:35-11:45 S06-3 TBD
11:45-11:55 S06-4 TBD
11:55-12:05 S06-5 TBD
12:05-12:15 S06-6 TBD
12:15-12:45 Lunch Seminar: TBD
12:15-12:45 LS1 TBD
13:15-13:55 Plenary 4: Aptamer Therapeutics & Clinical Translation
13:15-13:55

PL04 Preclinical and Clinical Development of Anticoagulant and Thrombolytic Aptamers and Reversal Agents

Bruce Sullenger (Duke University, USA)
13:55-15:15 Session 7. Aptamers & ASO
13:55-14:20 S07-1 Ichiro Hirao (Xenolis Pte Ltd, Singapore)
14:20-14:45 S07-2 TBD
14:45-15:00 S07-3 Jeong Ho Lee (KAIST, Korea)
15:00-15:15 S07-4 Il-Hoan Oh (RegenInnopharm, Korea)
15:35-17:15 Session 8. Oligonucleotide Development — Tox, CMC & Regulatory
15:35-16:00

S08-1 Zilganersen in Alexander Disease: Translational Pharmacology, CNS Delivery, and Intrathecal Safety

Tae-Won Kim (Ionis Pharmaceuticals, USA)
16:00-16:25

S08-2 From Chiral Monomers to Stereopure Oligonucleotides: Synthesis and NMR Characterization

Ik-Hyeon Paik (Wave Life Sciences, USA)
16:25-16:50

S08-3 CMC and Current Regulatory Guidelines for Oligonucleotide Therapeutics

Thomas Rupp (Thomas Rupp Consulting UG, Germany)
16:50-17:15 S08-4

TBD
TOP